Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Pacira BioSciences, Inc. (PCRX)
|
Add to portfolio |
|
|
|
| Price: |
$61.20
| | Metrics |
| OS: |
46.0
|
M
| |
|
|
| Market cap: |
$2.81
|
B
| |
|
|
|
Net debt:
|
$510
|
M
| |
|
|
|
EV:
|
$3.32
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 666.8 | 541.5 | 429.6 | 418.9 | 332.4 | 284.3 | 276.4 | 249.0 |
| Revenue growth | 23.1% | 26.0% | 2.6% | 26.0% | 16.9% | 2.9% | 11.0% | 26.0% |
| Cost of goods sold | 199.3 | 140.3 | 117.3 | 106.7 | 86.8 | 87.9 | 110.1 | 71.8 |
| Gross profit | 467.5 | 401.3 | 312.3 | 312.2 | 245.6 | 196.4 | 166.3 | 177.2 |
| Gross margin | 70.1% | 74.1% | 72.7% | 74.5% | 73.9% | 69.1% | 60.2% | 71.1% |
| Selling, general and administrative | 254.5 | 199.3 | 193.5 | 200.8 | 177.3 | 161.5 | 152.6 | 139.0 |
| Research and development | 84.8 | 55.5 | 59.4 | 72.1 | 55.7 | 57.3 | 45.7 | 28.7 |
| EBITA | 117.3 | 103.5 | 54.2 | 16.2 | 15.9 | -24.9 | -32.0 | 9.8 |
| EBITA margin | 17.6% | 19.1% | 12.6% | 3.9% | 4.8% | -8.8% | -11.6% | 3.9% |
| Amortization of intangibles | 57.3 | 13.6 | 7.9 | 5.7 | | | | 0.3 |
| EBIT | 60.0 | 89.9 | 46.4 | 10.5 | 15.9 | -24.9 | -32.0 | 9.5 |
| EBIT margin | 9.0% | 16.6% | 10.8% | 2.5% | 4.8% | -8.8% | -11.6% | 3.8% |
| Pre-tax income | 13.3 | 56.4 | 20.1 | -10.7 | -0.4 | -42.5 | -37.8 | 2.1 |
| Income taxes | -2.6 | 14.4 | -125.4 | 0.3 | 0.0 | 0.1 | 0.1 | 0.3 |
| Tax rate | | 25.6% | | | | | | 12.5% |
| Net income | 15.9 | 42.0 | 145.5 | -11.0 | -0.5 | -42.6 | -37.9 | 1.9 |
| Net margin | 2.4% | 7.8% | 33.9% | -2.6% | -0.1% | -15.0% | -13.7% | 0.7% |
| |
| Diluted EPS | $0.34 | $0.92 | $3.33 | ($0.27) | ($0.01) | ($1.07) | ($1.02) | $0.04 |
| Shares outstanding (diluted) | 46.5 | 45.6 | 43.7 | 41.5 | 40.9 | 39.8 | 37.2 | 41.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|